Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02792218




Registration number
NCT02792218
Ethics application status
Date submitted
2/06/2016
Date registered
7/06/2016
Date last updated
1/10/2021

Titles & IDs
Public title
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Scientific title
A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Secondary ID [1] 0 0
2015-005418-31
Secondary ID [2] 0 0
COMB157G2301
Universal Trial Number (UTN)
Trial acronym
ASCLEPIOS I
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ofatumumab subcutaneous injection
Treatment: Drugs - Teriflunomide-matching placebo capsules
Treatment: Drugs - Teriflunomide capsule
Treatment: Drugs - Matching placebo of ofatumumab subcutaneous injections

Experimental: OMB 20 mg - Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily

Active comparator: TER 14 mg - Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter


Treatment: Drugs: Ofatumumab subcutaneous injection
Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter

Treatment: Drugs: Teriflunomide-matching placebo capsules
Placebo capsule, matching in appearance to teriflunomide, taken orally once daily

Treatment: Drugs: Teriflunomide capsule
Teriflunomide 14 mg oral capsule taken once daily

Treatment: Drugs: Matching placebo of ofatumumab subcutaneous injections
Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized Relapse Rate (ARR)
Timepoint [1] 0 0
Baseline up to 2.5 years
Secondary outcome [1] 0 0
3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Pooled Data
Timepoint [1] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [2] 0 0
3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Study COMB157G2301
Timepoint [2] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [3] 0 0
6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Pooled Data
Timepoint [3] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [4] 0 0
6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Study COMB157G2301
Timepoint [4] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [5] 0 0
6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Pooled Data
Timepoint [5] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [6] 0 0
6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Study COMB157G2301
Timepoint [6] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [7] 0 0
Number of Gd-enhancing T1 Lesions Per MRI Scan
Timepoint [7] 0 0
Baseline, yearly up to 2.5 years
Secondary outcome [8] 0 0
Number of New or Enlarging T2 Lesions on MRI Per Year (Annualized Lesion Rate)
Timepoint [8] 0 0
Baseline, yearly up to 2.5 years
Secondary outcome [9] 0 0
Neurofilament Light Chain (NfL) Concentration in Serum
Timepoint [9] 0 0
Month 3, 12 and 24
Secondary outcome [10] 0 0
Annualized Rate of Brain Volume Loss Based on Assessments of Percent Brain Volume Change From Baseline
Timepoint [10] 0 0
Baseline, months 12 and 24
Secondary outcome [11] 0 0
Percentage of Participants With Confirmed Relapse
Timepoint [11] 0 0
Baseline up to 2.5 years
Secondary outcome [12] 0 0
Annualized Relapse Rate (ARR) >8 Weeks After Onset of Treatment
Timepoint [12] 0 0
Baseline up to 2.5 years
Secondary outcome [13] 0 0
3-month Confirmed Disability Worsening (3mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data
Timepoint [13] 0 0
Baseline up to 2.5 years
Secondary outcome [14] 0 0
6-month Confirmed Disability Worsening (6mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data
Timepoint [14] 0 0
Baseline up to 2.5 years
Secondary outcome [15] 0 0
6-month Confirmed Cognitive Decline on Symbol Digit Modalities Test (SDMT) - Pooled Data
Timepoint [15] 0 0
Baseline, every 6 months up to 2.5 years
Secondary outcome [16] 0 0
6-month Confirmed Disability Worsening (6mCDW) or 6-month Confirmed Cognitive Decline (6mCCD) - Pooled Data
Timepoint [16] 0 0
Baseline up to 2.5 years
Secondary outcome [17] 0 0
Change in Cognitive Performance Measured by the Symbol Digit Modalities Test (SDMT) - Pooled Data
Timepoint [17] 0 0
Baseline up to 2.5 years
Secondary outcome [18] 0 0
6-month Confirmed Worsening of at Least 20% in the Timed 25-Foot Walk (T25FW) - Pooled Data
Timepoint [18] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [19] 0 0
6-month Confirmed Worsening of at Least 20% in the 9-Hole Peg Test (9HPT) - Pooled Data
Timepoint [19] 0 0
Baseline, every 6 months up to 2.5 years
Secondary outcome [20] 0 0
6-month Confirmed Disability Improvement (6mCDI) Sustained Until End of Study (EOS) as Measured by EDSS - Pooled Data
Timepoint [20] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [21] 0 0
Number of New or Enlarging T2 Lesions on MRI Per Year From Month 12 Until End of Study (EOS)
Timepoint [21] 0 0
Month 12 up to 2.5 years
Secondary outcome [22] 0 0
Percent Change in T2 Lesion Volume Relative to Baseline
Timepoint [22] 0 0
Baseline, Month 12, Month 24
Secondary outcome [23] 0 0
No Evidence of Disease Activity (NEDA-4)
Timepoint [23] 0 0
Baseline, Month 12, Month 24
Secondary outcome [24] 0 0
Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score Change From Baseline
Timepoint [24] 0 0
Baseline, every 6 months up to 2.5 years
Secondary outcome [25] 0 0
Multiple Sclerosis Impact Scale (MSIS-29) Psychological Impact Score Change From Baseline
Timepoint [25] 0 0
Baseline, every 6 months up to 2.5 years
Secondary outcome [26] 0 0
Annualized Relapse Rates (ARR) by NfL High-low Subgroups - Pooled Data
Timepoint [26] 0 0
Baseline up to 2.5 years
Secondary outcome [27] 0 0
Number of New or Enlarging T2 Lesions Per Year by NfL High-low Subgroups - Pooled Data
Timepoint [27] 0 0
Baseline, yearly up to 2.5 years
Secondary outcome [28] 0 0
Annual Rate of Percent Change in Brain Volume Loss by NfL High-low Subgroups - Pooled Data
Timepoint [28] 0 0
Baseline, Months 12 and 24
Secondary outcome [29] 0 0
Pharmacokinetic (PK) Concentrations of Ofatumumab
Timepoint [29] 0 0
Baseline, Weeks 4, 12, 24, 48, 96

Eligibility
Key inclusion criteria
* 18 to 55 years of age
* Diagnosis of multiple sclerosis (MS)
* Relapsing MS: relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
* At least 1 relapse during the previous 1 year or 2 relapses during the previous 2 years or a positive gadolinium-enhancing MRI scan in previous year
* Expanded disability status scale (EDSS) score of 0 to 5.5
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Primary progressive MS
* Disease duration of more than 10 years in patients with an EDSS score of 2 or less
* Patients with an active chronic disease of the immune system other than MS
* Patients at risk of developing or having reactivation of hepatitis
* Patients with active systemic infections or with neurological findings consistent with PML

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/09/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/07/2020
Sample size
Target
Accrual to date
Final
930
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Novartis Investigative Site - New Lambton Heights
Recruitment hospital [2] 0 0
Novartis Investigative Site - St Leonards
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Hawaii
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nevada
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Santa Fe
Country [26] 0 0
Argentina
State/province [26] 0 0
Buenos Aires
Country [27] 0 0
Argentina
State/province [27] 0 0
Cordoba
Country [28] 0 0
Belgium
State/province [28] 0 0
Brasschaat
Country [29] 0 0
Belgium
State/province [29] 0 0
Brugge
Country [30] 0 0
Belgium
State/province [30] 0 0
Liege
Country [31] 0 0
Belgium
State/province [31] 0 0
Pelt
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Plovdiv
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Sofia
Country [34] 0 0
Canada
State/province [34] 0 0
British Columbia
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Croatia
State/province [36] 0 0
HRV
Country [37] 0 0
Croatia
State/province [37] 0 0
Zagreb
Country [38] 0 0
Czechia
State/province [38] 0 0
Czech Republic
Country [39] 0 0
Czechia
State/province [39] 0 0
CZE
Country [40] 0 0
Czechia
State/province [40] 0 0
JIhlava
Country [41] 0 0
Czechia
State/province [41] 0 0
Pardubice
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha 5
Country [43] 0 0
Denmark
State/province [43] 0 0
Aarhus
Country [44] 0 0
Denmark
State/province [44] 0 0
Copenhagen
Country [45] 0 0
Denmark
State/province [45] 0 0
Odense C
Country [46] 0 0
Estonia
State/province [46] 0 0
Tallinn
Country [47] 0 0
Estonia
State/province [47] 0 0
Tartu
Country [48] 0 0
France
State/province [48] 0 0
Cedex
Country [49] 0 0
France
State/province [49] 0 0
Lille Cedex
Country [50] 0 0
France
State/province [50] 0 0
Nantes Cedex 1
Country [51] 0 0
France
State/province [51] 0 0
Nimes Cedex
Country [52] 0 0
Germany
State/province [52] 0 0
Barsinghausen
Country [53] 0 0
Germany
State/province [53] 0 0
Bayreuth
Country [54] 0 0
Germany
State/province [54] 0 0
Bielefeld
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Marburg
Country [57] 0 0
Germany
State/province [57] 0 0
Muenchen
Country [58] 0 0
Germany
State/province [58] 0 0
Neuburg an der Donau
Country [59] 0 0
Germany
State/province [59] 0 0
Potsdam
Country [60] 0 0
Germany
State/province [60] 0 0
Ulm
Country [61] 0 0
Germany
State/province [61] 0 0
Wiesbaden
Country [62] 0 0
Greece
State/province [62] 0 0
GR
Country [63] 0 0
Greece
State/province [63] 0 0
Athens
Country [64] 0 0
Greece
State/province [64] 0 0
Thessaloniki
Country [65] 0 0
Hungary
State/province [65] 0 0
HUN
Country [66] 0 0
Hungary
State/province [66] 0 0
Budapest
Country [67] 0 0
Hungary
State/province [67] 0 0
Kistarcsa
Country [68] 0 0
Hungary
State/province [68] 0 0
Szeged
Country [69] 0 0
India
State/province [69] 0 0
Delhi
Country [70] 0 0
India
State/province [70] 0 0
Karnataka
Country [71] 0 0
India
State/province [71] 0 0
Kerala
Country [72] 0 0
India
State/province [72] 0 0
Punjab
Country [73] 0 0
India
State/province [73] 0 0
West Bengal
Country [74] 0 0
India
State/province [74] 0 0
Mangalore
Country [75] 0 0
Israel
State/province [75] 0 0
Ashkelon
Country [76] 0 0
Israel
State/province [76] 0 0
Haifa
Country [77] 0 0
Israel
State/province [77] 0 0
Sefad
Country [78] 0 0
Israel
State/province [78] 0 0
Tel Aviv
Country [79] 0 0
Italy
State/province [79] 0 0
MI
Country [80] 0 0
Italy
State/province [80] 0 0
RM
Country [81] 0 0
Italy
State/province [81] 0 0
VA
Country [82] 0 0
Italy
State/province [82] 0 0
Napoli
Country [83] 0 0
Mexico
State/province [83] 0 0
Distrito Federal
Country [84] 0 0
Netherlands
State/province [84] 0 0
BG
Country [85] 0 0
Netherlands
State/province [85] 0 0
Amsterdam
Country [86] 0 0
Netherlands
State/province [86] 0 0
Rotterdam
Country [87] 0 0
Poland
State/province [87] 0 0
Bydgoszcz
Country [88] 0 0
Poland
State/province [88] 0 0
Gdansk
Country [89] 0 0
Poland
State/province [89] 0 0
Katowice
Country [90] 0 0
Poland
State/province [90] 0 0
Kielce
Country [91] 0 0
Poland
State/province [91] 0 0
Lodz
Country [92] 0 0
Puerto Rico
State/province [92] 0 0
Guaynabo
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Kemerovo
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Moscow
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Nizhny Novgorod
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Novosibirsk
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Saint Petersburg
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Saransk
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Sestroretsk
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Tyumen
Country [101] 0 0
Slovakia
State/province [101] 0 0
Banska Bystrica
Country [102] 0 0
Slovakia
State/province [102] 0 0
Bratislava
Country [103] 0 0
Slovakia
State/province [103] 0 0
Nitra
Country [104] 0 0
Slovakia
State/province [104] 0 0
Trnava
Country [105] 0 0
Spain
State/province [105] 0 0
Andalucia
Country [106] 0 0
Spain
State/province [106] 0 0
Cataluna
Country [107] 0 0
Spain
State/province [107] 0 0
Catalunya
Country [108] 0 0
Spain
State/province [108] 0 0
Cataluña
Country [109] 0 0
Spain
State/province [109] 0 0
Murcia
Country [110] 0 0
Spain
State/province [110] 0 0
Barcelona
Country [111] 0 0
Spain
State/province [111] 0 0
Valencia
Country [112] 0 0
Sweden
State/province [112] 0 0
Goeteborg
Country [113] 0 0
Sweden
State/province [113] 0 0
Stockholm
Country [114] 0 0
Switzerland
State/province [114] 0 0
Basel
Country [115] 0 0
Thailand
State/province [115] 0 0
THA
Country [116] 0 0
Turkey
State/province [116] 0 0
Istanbul
Country [117] 0 0
Turkey
State/province [117] 0 0
Izmir
Country [118] 0 0
Turkey
State/province [118] 0 0
Kocaeli
Country [119] 0 0
Turkey
State/province [119] 0 0
Samsun
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Oxfordshire
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Glasgow
Country [122] 0 0
United Kingdom
State/province [122] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Trial website
https://clinicaltrials.gov/study/NCT02792218
Trial related presentations / publications
Gartner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Haring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022 Sep;28(10):1562-1575. doi: 10.1177/13524585221078825. Epub 2022 Mar 10.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Haring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02792218